Evaluating Study Drug BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Brief description of study

The research study is being conducted to investigate if the study drug BIIB059 can reduce disease activity and inflammation in people with active Cutaneous Lupus Erythematosus compared to a placebo. Participants will complete the following research procedures: demography and medical history, previous CLE therapy, SARS-CoV-2 (COVID-19) test, chest X-ray, skin biopsy, Systemic Lupus Erythematosus (SLE) assessment, skin assessments, skin photography, physical examination, vital signs, electrocardiogram (ECG), diary review, questionnaires, blood and urine tests, concomitant therapies/procedures, recording of signs or symptoms of illness, optional blood test for genetic research, optional future scientific research. Participation will last for 80 weeks (about 18 months) in total.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Lupus,Cutaneous Lupus Erythematosus
Age: Between 18 Years - 99 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 852092

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).